Efficacy of low-dose cyclosporine in severe atopic skin disease

Joost, Th. van

doi:10.1001/archderm.123.2.166

Cited by 74 publications

(23 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since Van Joost et al [20]reported 2 patients with severe AD who improved considerably within 10 days of receiving CsA at a dose of 5 mg/kg/day, its efficacy has been confirmed in a number of double-blind placebo-controlled multicenter studies [21]. …”

Section: Introductionmentioning

confidence: 99%

Soluble CD30 and Cyclosporine in Severe Atopic Dermatitis

Caproni

Salvatore

Cardinali

et al. 2000

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Allergen-reactive Th2-like cells expressing membrane CD30 are present in the circulation of atopic dermatitis (AD) patients during seasonal allergen exposure. Moreover, CD30+ T cells are present in the lesional skin of AD patients and high levels of soluble CD30 (sCD30) are found in the serum of the same atopic patients. To investigate the immunosuppressive capacity of cyclosporin A (CsA) in AD patients, the sCD30 serum level was determined before and after CsA treatment (5 mg/kg/day) in 10 patients with severe, refractory AD. The sCD30 serum levels before and after CsA therapy together with other serum parameters were correlated with disease activity. Methods: sCD30 serum levels were detected using a commercial sandwich ELISA; serum eosinophil cationic protein (ECP) levels were determined using a radioimmunoassay (RIA). Results: In all AD patients sCD30 serum levels were increased ranging from 36 to 300 U/ml, with a mean value equal to 135.7 U/ml. After 6 weeks of CsA treatment, not only was there a significant difference between serum sCD30 levels before (mean 135.7) and after (mean 96.2) treatment but even the serum ECP levels before (mean 57.78) and after (mean 18.69) therapy showed an important reduction. Moreover, no significant difference was found between the mean of serum IgE levels before and after treatment, although the values showed a correlation (p = 0.0003). No significant correlations could be demonstrated between sCD30 levels and serum IgE or between sCD30 and ECP serum levels nor between sCD30 levels and blood eosinophil count after CsA treatment. Moreover, a positive correlation (p = 0.001) was instead documented between sCD30 and the severity of the disease. Conclusions: In this study, CsA therapy results in clinical improvement together with a statistically significant reduction in sCD30 and ECP serum levels in AD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Soluble CD30 and Cyclosporine in Severe Atopic Dermatitis

Caproni

Salvatore

Cardinali

et al. 2000

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8] The side effects of CsA, such as nephrotoxicity and hepatoxicity, as well as gingival alteration, were noticed during the initial clinical evaluation of the drug. 1,2 The occurrence of CsA-induced gingival overgrowth has been substantially reported in the dental literature.…”

mentioning

confidence: 99%

Cyclosporin‐Induced Gingival Overgrowth at the Newly Formed Edentulous Ridge in Rats: A Morphological and Histometric Evaluation

Hsieh

Shen

et al. 2001

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…Finally, I wotild like to discuss the dermatologic applications of cyclospwrine in AD. Vanjoost et al (30) were the first to note the beneficial effects of the drug on severe disease. They treated two patients with severe drug-resistant disease with 5 mg/kg/day of cyclosporine, and near complete remission (>SK)%) was observed in both after four weeks of therapy.…”

Section: Desperation or Experimental Therapymentioning

confidence: 99%

Advances in Nondietary Management of Children with Atopic Dermatitis

Rasmussen

1989

Pediatric Dermatology

View full text Add to dashboard Cite

This paper discusses recent advances in therapy of atopic dermatitis (AD), excluding those that include dietary management. Some of these therapies are anecdotal, experimental, or somewhat controversial. It is important to emphasize that physicians should not try what is new without first having given standard therapy a long and reasonable chance to succeed. This is important because AD does not last forever, and in many patients, mild disease heals spontaneously.

show abstract

Efficacy of low-dose cyclosporine in severe atopic skin disease

Cited by 74 publications

References 6 publications

Soluble CD30 and Cyclosporine in Severe Atopic Dermatitis

Soluble CD30 and Cyclosporine in Severe Atopic Dermatitis

Cyclosporin‐Induced Gingival Overgrowth at the Newly Formed Edentulous Ridge in Rats: A Morphological and Histometric Evaluation

Advances in Nondietary Management of Children with Atopic Dermatitis

Contact Info

Product

Resources

About